Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved OTC

5

Other

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

C55-isoprenyl pyrophosphate

5

lipid particle

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

5

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1921

5

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Infection

5

Skin diseases

5

Superficial infections of the external eye and its adnexa caused by susceptible bacteria

5

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Curative

5

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Goorley, J.T.

5

Thorpe, J.F.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Mixture

4

Chemical

2

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

FDA UNII

6

MERCK INDEX

6

CAS

5

ECHA (EC/EINECS)

5

CFR

4

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

DERMATOLOGICALS

2

ANTIINFECTIVES FOR SYSTEMIC USE

1

CARDIOVASCULAR SYSTEM

1

RESPIRATORY SYSTEM

1

SENSORY ORGANS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIBACTERIALS FOR SYSTEMIC USE

1

ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE

1

MEDICATED DRESSINGS

1

OPHTHALMOLOGICALS

1

THROAT PREPARATIONS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE

1

ANTIBIOTICS FOR TOPICAL USE

1

ANTIINFECTIVES

1

MEDICATED DRESSINGS

1

OTHER ANTIBACTERIALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Antibiotics

1

Other agents for treatment of hemorrhoids and anal fissures for topical use

1

Other antibacterials

1

Other antibiotics for topical use

1

Other antiinfectives

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

4

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 6 of 6 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

NILE RED

P476F1L81G

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Conditions:

Nile red (9-diethylamino-5H-benzo[alpha]phenoxazine-5-one) is an excellent vital stain for the detection of intracellular lipid droplets by fluorescence microscopy and flow cytofluorometry. It has environment-sensitive fluorescence. Nile red is inte...

nsely fluorescent in a lipid-rich environment while it has minimal fluorescence in aqueous media. Better selectivity for cytoplasmic lipid droplets can be obtained when the cells are viewed with yellow-gold fluorescence (450-500 nm excitation; >528 nm emission) rather than red fluorescence (515-560 nm excitation; >590 nm emission). Nile red is strongly fluorescent, but only in a hydrophobic environment.

Bacitracin

58H6RWO52I

Status:

US Approved OTC

First marketed in 1921

Class:

MIXTURE

Targets:

C55-isoprenyl pyrophosphate

Conditions:

Superficial infections of the external eye and its adnexa caused by susceptible bacteria

Bacitracin is a polypeptide antibiotic produced by Bacillus subtilis and Bacillus licheniformis. Bacitracin in combination with neomycin and polymyxin B is indicated for the treatment of many bacterial diseases. The antibacterial properties of bacitr...

acin are mediated by its binding to C55-isoprenyl pyrophosphate, resulting in inhibition of cell wall biosynthesis.

ZINC

J41CSQ7QDS

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

C55-isoprenyl pyrophosphate

Conditions:

Superficial infections of the external eye and its adnexa caused by susceptible bacteria

Bacitracin is a polypeptide antibiotic produced by Bacillus subtilis and Bacillus licheniformis. Bacitracin in combination with neomycin and polymyxin B is indicated for the treatment of many bacterial diseases. The antibacterial properties of bacitr...

acin are mediated by its binding to C55-isoprenyl pyrophosphate, resulting in inhibition of cell wall biosynthesis.

BACITRACIN METHYLENEDISALICYLATE SODIUM

1EJ7TZQ03Q

Status:

US Approved OTC

First marketed in 1921

Class:

MIXTURE

Targets:

C55-isoprenyl pyrophosphate

Conditions:

Superficial infections of the external eye and its adnexa caused by susceptible bacteria

Bacitracin is a polypeptide antibiotic produced by Bacillus subtilis and Bacillus licheniformis. Bacitracin in combination with neomycin and polymyxin B is indicated for the treatment of many bacterial diseases. The antibacterial properties of bacitr...

acin are mediated by its binding to C55-isoprenyl pyrophosphate, resulting in inhibition of cell wall biosynthesis.

BACITRACIN METHYLENEDISALICYLATE

JGV6OJ52FT

Status:

US Approved OTC

First marketed in 1921

Class:

MIXTURE

Targets:

C55-isoprenyl pyrophosphate

Conditions:

Superficial infections of the external eye and its adnexa caused by susceptible bacteria

Bacitracin is a polypeptide antibiotic produced by Bacillus subtilis and Bacillus licheniformis. Bacitracin in combination with neomycin and polymyxin B is indicated for the treatment of many bacterial diseases. The antibacterial properties of bacitr...

acin are mediated by its binding to C55-isoprenyl pyrophosphate, resulting in inhibition of cell wall biosynthesis.

BACITRACIN ZINC

89Y4M234ES

Status:

US Approved OTC

First marketed in 1921

Class:

MIXTURE

Targets:

C55-isoprenyl pyrophosphate

Conditions:

Superficial infections of the external eye and its adnexa caused by susceptible bacteria

Bacitracin is a polypeptide antibiotic produced by Bacillus subtilis and Bacillus licheniformis. Bacitracin in combination with neomycin and polymyxin B is indicated for the treatment of many bacterial diseases. The antibacterial properties of bacitr...

acin are mediated by its binding to C55-isoprenyl pyrophosphate, resulting in inhibition of cell wall biosynthesis.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1